Kwality Pharmaceuticals Limited (BOM:539997)
755.00
-42.10 (-5.28%)
At close: Apr 24, 2025
Kwality Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
Operating Revenue | 3,465 | 3,072 | 2,510 | 4,562 | 2,620 | 1,393 | Upgrade
|
Other Revenue | - | - | - | - | 10.42 | 32.08 | Upgrade
|
Revenue | 3,465 | 3,072 | 2,510 | 4,562 | 2,631 | 1,425 | Upgrade
|
Revenue Growth (YoY) | 22.01% | 22.36% | -44.97% | 73.42% | 84.59% | -14.50% | Upgrade
|
Cost of Revenue | 1,726 | 1,580 | 1,136 | 2,051 | 1,716 | 901.36 | Upgrade
|
Gross Profit | 1,739 | 1,492 | 1,375 | 2,511 | 914.74 | 523.69 | Upgrade
|
Selling, General & Admin | 401.66 | 326.29 | 301.26 | 202.76 | 160.1 | 123.53 | Upgrade
|
Other Operating Expenses | 570.48 | 485.2 | 456.86 | 573.94 | 452.81 | 226.12 | Upgrade
|
Operating Expenses | 1,155 | 1,007 | 907.71 | 883.61 | 677.85 | 393.98 | Upgrade
|
Operating Income | 584.6 | 484.53 | 466.8 | 1,627 | 236.9 | 129.71 | Upgrade
|
Interest Expense | -104.42 | -103.87 | -60.2 | -29.17 | -26.75 | -25.03 | Upgrade
|
Interest & Investment Income | 1.3 | 1.3 | 1.23 | 1.23 | 1.81 | 1.9 | Upgrade
|
Currency Exchange Gain (Loss) | - | - | 12.66 | 16.62 | 0.96 | 1.53 | Upgrade
|
Other Non Operating Income (Expenses) | - | - | -0 | -0 | - | - | Upgrade
|
EBT Excluding Unusual Items | 481.47 | 381.96 | 420.48 | 1,616 | 212.91 | 108.11 | Upgrade
|
Gain (Loss) on Sale of Assets | 0.02 | 0.02 | 0.54 | - | -0.2 | 1.06 | Upgrade
|
Asset Writedown | - | - | -70.51 | - | - | - | Upgrade
|
Other Unusual Items | -70.99 | -70.99 | -94.78 | - | - | - | Upgrade
|
Pretax Income | 410.5 | 310.99 | 255.72 | 1,616 | 212.72 | 109.17 | Upgrade
|
Income Tax Expense | 114.07 | 74.83 | 62.93 | 416.28 | 63.84 | 27.1 | Upgrade
|
Earnings From Continuing Operations | 296.44 | 236.16 | 192.8 | 1,199 | 148.88 | 82.07 | Upgrade
|
Minority Interest in Earnings | 1.6 | 1.8 | 0.93 | 0.53 | 2.58 | 1.1 | Upgrade
|
Net Income | 298.03 | 237.96 | 193.72 | 1,200 | 151.46 | 83.17 | Upgrade
|
Net Income to Common | 298.03 | 237.96 | 193.72 | 1,200 | 151.46 | 83.17 | Upgrade
|
Net Income Growth | 148.97% | 22.84% | -83.86% | 692.24% | 82.11% | 10.13% | Upgrade
|
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade
|
Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade
|
Shares Change (YoY) | -0.18% | - | - | 0.00% | - | - | Upgrade
|
EPS (Basic) | 28.91 | 22.93 | 18.67 | 115.64 | 14.60 | 8.02 | Upgrade
|
EPS (Diluted) | 28.91 | 22.93 | 18.67 | 115.64 | 14.60 | 8.02 | Upgrade
|
EPS Growth | 149.41% | 22.84% | -83.86% | 692.22% | 82.11% | 10.13% | Upgrade
|
Free Cash Flow | - | 131.42 | -62.92 | 54.45 | 33.06 | -146.14 | Upgrade
|
Free Cash Flow Per Share | - | 12.66 | -6.06 | 5.25 | 3.19 | -14.09 | Upgrade
|
Gross Margin | 50.20% | 48.56% | 54.75% | 55.04% | 34.77% | 36.75% | Upgrade
|
Operating Margin | 16.87% | 15.77% | 18.59% | 35.66% | 9.01% | 9.10% | Upgrade
|
Profit Margin | 8.60% | 7.75% | 7.72% | 26.30% | 5.76% | 5.84% | Upgrade
|
Free Cash Flow Margin | - | 4.28% | -2.51% | 1.19% | 1.26% | -10.26% | Upgrade
|
EBITDA | 814.69 | 680.12 | 616.38 | 1,734 | 301.83 | 174.05 | Upgrade
|
EBITDA Margin | 23.51% | 22.14% | 24.55% | 38.01% | 11.47% | 12.21% | Upgrade
|
D&A For EBITDA | 230.09 | 195.59 | 149.58 | 106.91 | 64.93 | 44.34 | Upgrade
|
EBIT | 584.6 | 484.53 | 466.8 | 1,627 | 236.9 | 129.71 | Upgrade
|
EBIT Margin | 16.87% | 15.77% | 18.59% | 35.66% | 9.01% | 9.10% | Upgrade
|
Effective Tax Rate | 27.79% | 24.06% | 24.61% | 25.77% | 30.01% | 24.83% | Upgrade
|
Revenue as Reported | 3,482 | 3,090 | 2,540 | 4,597 | 2,636 | 1,430 | Upgrade
|
Advertising Expenses | - | 0.66 | 1.67 | 1.25 | 0.73 | 3.89 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.